Pharmaceutical Executive Daily: FDA Plans to Remove Two Study Requirement for New Drug Approvals

Why It Matters

Regulatory flexibility can reshape drug development economics, while consolidation in virtual care strengthens market reach and patient engagement.

Key Takeaways

• FDA drops two‑study rule for select approvals
• Change could cut development time and costs
• Hims & Hers to buy Eucalyptus for $1.15B
• Deal expands digital‑health footprint globally
• Industry seeks to de‑bottleneck early‑stage trials

Pulse Analysis

The FDA’s decision to eliminate the two‑study mandate for specific approval tracks marks a significant departure from a decades‑old standard. Historically, sponsors had to demonstrate efficacy through two separate, well‑controlled trials, a requirement that often doubled the cost and duration of late‑stage development. By allowing a single robust study to suffice in qualifying pathways—particularly for drugs addressing high‑unmet‑need conditions—the agency aims to streamline evidentiary expectations without compromising safety. This regulatory flexibility could encourage more innovative candidates to enter the pipeline, especially from smaller biotech firms with limited resources.

Hims & Hers Health’s $1.15 billion acquisition of Eucalyptus underscores the rapid consolidation occurring in the digital‑health arena. Eucalyptus brings a suite of telemedicine and direct‑to‑consumer services that complement Hims & Hers’ existing portfolio of men’s and women’s health products. The deal not only broadens geographic reach but also deepens data assets, enabling more personalized care models and cross‑selling opportunities. Analysts view the transaction as a strategic bet on scaling virtual care platforms to capture a larger share of the post‑pandemic healthcare market, where consumers increasingly prefer online access to treatments.

Beyond regulatory and M&A headlines, the industry is intensifying efforts to de‑bottleneck early‑stage clinical trials. Sponsors and the FDA are exploring adaptive designs, real‑world evidence integration, and faster protocol reviews to cut the lengthy pre‑clinical and Phase I phases. Streamlining these initial steps can reduce downstream delays, lower overall development spend, and bring breakthrough therapies to patients more quickly. As these initiatives mature, they promise a more efficient innovation ecosystem, aligning scientific advancement with market demand and patient needs.